Skin-Sights from SDPA Fall

Welcome to this week's edition of Dermatology Times' LinkedIn newsletter!

This week, Dermatology Times traveled to Las Vegas, Nevada, to attend and cover the Society of Dermatology Physician Associates (SDPA) 22nd Annual Fall Dermatology Conference. Our team spoke with session speakers and expert dermatologists who addressed numerous topics of interest. View our comprehensive conference coverage here. If you'd like to keep up with conference pearls and insights as they happen live, be sure to sign up for our e-newsletter.

If you have questions, suggestions, or would like to contribute to a future edition, please contact us via LinkedIn or via email at [email protected].

?? Expert Insights - CONFERENCE EDITION

Explore clinical conference insights from: Renata Block , MMS, PA-C; Matthew Zirwas , MD; Michael Rubio , PA-C; Faseeha Raza PA-C ; Sara M. Wilchowski, DMSc, PA-C, DFAAPA ; Tracey Vlahovic , DPM; Jane Mast PhD, DMSc, MPAS ; Shanna Miranti, MPAS, PA-C; and Hilary Baldwin, MD.

"In the end, it’s always about: What can we do to make our patient better? And when we collaborate, we are learning from each other, we are gaining pearls. That’s why I love coming to conferences like this, because we are sitting down at the same table, and that is the most important thing to make our patients better."

"If I could put it in one word, everything you've learned about atopic dermatitis is wrong. I love having the chance to really reeducate people on what we now think about atopic dermatitis and how to take the best care of your patients."

Watch more from Dr Zirwas.

"SDPA continues to be a main education for our members and we're growing exponentially in the field. The more education and the more spotlight we're giving our derm PAs, the better."

"My number 1 goal would be to cause brand awareness, and letting people know why DPAF exists: to promote our programming, such as Medical Mission Academy, talks in a box, professional development, and research. And knowing all these, I'm very confident a lot of PAs would be interested in becoming part of it and volunteer for it."

"I cannot stress enough to collaborate with your current MSLs, because it not only helps you understand the role, but it helps you to better serve your patients."

"To me, it's just a very natural collaboration. I was the first podiatrist to do a fellowship in podiatric dermatology over 24 years ago. I was very fortunate to have people who believed in me in the dermatology world and in the podiatry world to do that. And since then, I've forged a path to combine the 2 worlds, and the dermatology world has had extremely open arms with me."

"It was just such an honor to be recognized, and I really enjoy giving back to the community and mentoring up-and-comers in the area of dermatology."

"We want dermatology PAs to know that sometimes it's not enough to just prescribe one topical generic medication. If we are going to use combination therapy, we really want to try to check each one of those 4 pillars of acne pathogenesis when creating regimens for our patients with acne."

"We want dermatology PAs to know that sometimes it's not enough to just prescribe one topical generic medication. If we are going to use combination therapy, we really want to try to check each one of those 4 pillars of acne pathogenesis when creating regimens for our patients with acne."

Watch more from Dr Baldwin.

?? Breaking News Brief

The FDA accepted Abeona Therapeutics ' resubmitted Biologics License Application for prademagene zamikeracel (pz-cel) to treat recessive dystrophic epidermolysis bullosa, setting a PDUFA target action date of April 29, 2025.

The FDA accepted the supplemental Biologics License Application for dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients aged 12 and older, based on positive phase 3 trial results. If approved by the target date of April 18, 2025, it will mark the first targeted therapy for CSU in over a decade.

Delgocitinib cream (Anzupgo) has been approved by Swissmedic as the first topical pan-JAK inhibitor for adults with moderate to severe chronic hand eczema in Switzerland. The approval is supported by phase 3 trials (DELTA 1, 2, and 3) and a head-to-head comparison with alitretinoin, demonstrating significant efficacy and safety.

?? Research Roundup

A recent study showed that adapinoid 0.5% cream is more effective and better tolerated than retinol 0.5% for treating visible signs of aging. Over 12 weeks, adapinoid significantly improved wrinkle severity and skin pigmentation, while also reducing facial erythema and transepidermal water loss, unlike retinol, which showed limited improvements.

A recent study found that only 28% of images in pediatric nurse practitioner textbooks depicted darker skin tones, highlighting a significant gap in medical education that contributes to healthcare disparities. This underrepresentation can lead to misdiagnoses.

?? Continuing Education Opportunities

Discover ways to further your education and knowledge of specific disease states by exploring CME opportunities from Physicians' Education Resource?, LLC (PER?) below.

For more information, visit PER's website or click on the graphics below.

Thank you for reading!